Inhibikase Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and welcome to the Jefferies Global Healthcare Conference in London. My name is Dennis Ding, biotech analyst here. I have the great pleasure of having Inhibikase Therapeutics here. We have the CEO, Mark Iwicki.
Welcome. Thank you very much, Dennis.
Great to be here. Before we kind of go into more about the business and some of the progress you guys have made, maybe talk a little bit high level around the company and what you guys have done this year and what you guys are looking forward to.
Yeah. This has been a super exciting year for Inhibikase. We kicked off a phase III program. We have 28 countries approved and 79 sites up and running, and that's really in the past kind of four to six months. So we're feeling great. We're achieving our internal expectations. There's been a tremendous amount of excitement from thought leaders, investigators, practicing physicians about the promise of imatinib. Most people know that imatinib had been studied before in the IMPRES trial by Novartis and had always felt like this would be a great product to bring to the market. I think in general, too, what you're seeing is antiproliferatives are of tremendous interest.
Of course, sotatercept is off to a great start in the U.S. and approved in many other countries. I think it is really opening up the market that these products alone and in combination in the future will really be the next standard of care.
Sure. Maybe talk a little bit more about PAH and just how that landscape is changing with sotatercept, and then just some of the other therapeutics that are in development and could be approved in the next few years.
It was dominated by vasodilators for 20 years, 30 years, and those products are great and they are needed and they are important, but they are limited in a way in their ability to really change the long-term course of the disease. Sotatercept, an activin trap product, is an antiproliferative agent, and our product, the kinase inhibitor IKT-001, which is going to deliver imatinib, is also an antiproliferative agent. That is really changing, I think, the framing of the disease and how it is going to be treated. We have already seen a bit of a downstreaming of sotatercept into the more moderate populations, and I think when you talk with the thought leaders, they are most excited about getting these products used earlier and earlier in the course of the disease. I think another piece of it, and we always get asked this question, well, does the market need multiple antiproliferative agents?
The answer to that is unequivocally yes. No single drug is going to be able to treat this disease. There is still going to be combination therapy used routinely. In fact, I think what we are going to see in the future is combinations of antiproliferatives used, and you will see some of the more complicated vasodilator products will be pushed to kind of last line. I think you are going to see these antiproliferative agents kind of be second-line therapy, and maybe even over time, they will be a beginning, a part of a starting regimen.
Sure. Okay. You guys are in phase III, that is enrolling, and you guys will have a number of updates in 2027, 2028, and 2029. Just remind us what those are, and maybe go into a little bit more detail around some of the safety updates that you guys will have next year.
Yeah. In 2027, what we have communicated is that we will provide what we have called a safety update, and that is going to look a lot like what other people have done during the blinded portion of a study. What we are obligated to do for a financing tranche is to have 50 patients into the study and 12 weeks worth of data. The obligation we have is just to report out that the DSMB has looked at that data and that the trial can continue, and we believe that that is probably the limit to the information it will provide. But what it will clearly do is show that we are executing well and that the trial is on track. Then a really exciting readout for us is mid-2028. That is the Part A of our study, which is 140 patients with a primary endpoint of PVR.
That often looks like a phase II study for other development programs. For us, we call that Part A, and that will be a full data set. PVR is how it is powered in the primary endpoint. We will have six-minute walk data. We will have other secondary endpoint data, so we are really excited about that. Then the pivotal data comes in mid-2029. Think of it as first half 2027 for a safety update, study is on track and rolling nicely, mid-2028, a pretty definitive data set with PVR being a highlight there, and then mid-2029, that pivotal data that we will be able to file upon. Our program is pretty interesting in a way because what we have done is have a Part A and a Part B, but we use the same sites.
As soon as the last patient is enrolled in Part A, the next patient goes right into Part B, and that will give us two independent data sets and hopefully a really good package for filing.
For the safety update next year, 50 patients worth of data, 12 weeks of follow-up, but you also said limited disclosure. I guess help us understand what exactly the DSMB is looking, what will be communicated to you, and could you guys look at perhaps blinded PVR at that point?
Yeah, look, I guess the answer to that question is we could certainly look at everything, but because it's such a small data set, just 50 patients, in principle, 25 on drug, 25 on placebo, we're likely to just stick with what we're obligated to do. That brings in a $55 million financing for us, just to be able to have the DSMB say that there are no meaningful issues that would make them want to stop the trial and that the trial could continue. It's very fair for everyone to ask investors, analysts, you'll have more data, could you report blinded information? Of course, we will have that data, but we think we'll just stick to the requirement that we have in the financing.
Okay. Maybe I'll push on that a little bit more.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
